ArticleFrontiers in oncology2022

Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer.

Jiaoxue He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.